January 12, 2018 4:50pm

The sector opened up, stayed up at mid-day and closed to the downside

 

As the market hits new highs and indexes respond together … sector volume is relatively low for the upsiders and higher for the downsized

The IBB (+0.67%), XBI (+0.52%), XLV (+0.77%), NADAQ (+0.68%) and VIX (+2.73%) are up

 

Is it better to leave cents on the table by selling than losing a quarter by staying?

We are all ready for a three (3) day weekend – a NO market Monday is needed!

 

Pre-open indications: 3 hits and 2 miss (by pennies)

interest: Drug makers see a pricing blueprint in an $850,000 gene therapy https://www.reuters.com/article/us-healthcare-conference-pricing-analysi/drugmakers-see-a-pricing-blueprint-in-an-850000-gene-therapy-idUSKBN1F11D2

 

Out and about: The Biostage (BSTG +$0.14) chronicles … don’t be fooled by surges!


Friday’s results have implications to Monday’s sector activity as a daily report may say little or a lot and it serves as insurance that all indications are being examined and evaluated!

 

 

Henry’omics:

From the pre-open’s newsletter, “momentum has been fading in and out while volume remains low and relative strength lines are also low. Sentiment augmented by ETFs and algorithms doesn’t facilitate any immediate high ground. Sector companies are also preparing their Q4 and end-of-year (EOY) numbers reflecting cash and “runway” positions. Let’s see who has a pole position in jumping through the offering “window” in Q1/18?”

U.S. equities and bond markets will be closed for Martin Luther King Jr. Day on Monday, 1/15/18.

So far this week, the Dow is up 1.9% while the S&P is up 1.4% and the NASDAQ is up 1.5%. This is poised to be the second straight weekly gain for the Dow and the S&P, as well as their seventh positive week of the past eight.

The Russell 2000 (RUT) gained 0.3% to 1,590.86. The index of small-capitalization stocks hit an intraday record, and is up 1.9% on the week, which is set to be its biggest weekly gain since September.

Q4/16 earnings season unofficially kicked off on today and …

Today’s moves aren’t about fundamentals, but recognizing some oversold and many speculative upsides p. After many negative moves traders and algorithms pushed to buy dips.

Will that last - NO.

 

 

The advance/decline line scenario of 40 SCGT & RT covered companies:    

·         The open was positive with an A/DL of 27/10 and 3 flat – the reverse of yesterday;

·         The mid-day was positive with an A/DL of 21/15 and 4 flat;

·         The close was negative with an A/DL of 19/21 and 0 flat;

 

 

MY working trend lines and indications:

The greatest volume to the downside:  CYTX, RENE.L, MDXG, JUNO and ONVO  

Upside volume was weighted to:  NWBO, XON, FCSC, PSTI and RGNX

Biggest $ downside: OMCE (-$1.41), JUNO (-$1.34), BLUE (-$0.95), QURE (-$0.93) and HSGX (-$0.14)

Largest $ upside:  XON (+$1.48), SGMO (+$1/15), RGNX (+$0.55), CLLS (+0.26) and STML (+$0.25)

Flat: NONE

 

Pre-open indications:

  • Applied Genetic Technologies (AGTC) closed down - $0.10 – hit;
  • Capricor (CAPR) closed up +$0.03 – miss; be ready for an offering
  • Pluristem (PSTI) closed up +$0.09 – hit;
  • Vericel (VCEL) closed up + $0.18 – miss;
  • Verastem (VSTM) closed up again +$0.04 – hit;

 

 

Of interest:  

Drug makers see a pricing blueprint in an $850,000 gene therapy <Caroline Humer, Reuters>

Global drugmakers are looking to a tiny biotech’s $850,000 therapy for a rare type of blindness as a model for getting paid for highly expensive – and effective – new medicines. … https://www.reuters.com/article/us-healthcare-conference-pricing-analysi/drugmakers-see-a-pricing-blueprint-in-an-850000-gene-therapy-idUSKBN1F11D

 

 

Out and about:

Biostage (BSTGD) This management team WIPED OUT 20 M of holder’s shares and investment!

Opened at $2.00 (previous closed $2.00) closed +$0.14 or +7% in a day’s range of $2.00 to $2.94 to close at $2.14 with low 12,655 shares traded; the share price had been down as much as -$0.32.  This follows the projected $1.32 post the 1-to-20 reverse split – a $4 M in-flow just followed a $30 M investment loss incurring a $47 M deficit!

NO scientists, a CEO, CFO and 2 accountants don’t make a company who couldn’t pay their rent or communicate their issues to past “fleeced” shareholders …

I am NOT “eating” my negative declaration, my OPINION is still “COVER UP of male and female harassment and corporate MISDEEDS “by members of management team!

What did happen to (reasons) and the story “around” the IND NOT being filed and the cmo and president leaving the company? NEVER forget the storyline of the 2 broken financings before the reverse split!

 

 

Daily analytics:

U.S. stocks advanced on Friday, with major indexes adding to their recent string of records fueled by optimism over the economy and the state of American corporations as the fourth-quarter earnings season began.

·         The Dow rose 194 points, or 0.8%, to 25,768.

·         The S&P 500 added 17 points to 2,784, a gain of 0.6%.

·         The NASDAQ rose 45 points to 7,256, a gain of 0.6%.

 

The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, Friday traded at 10.15, up +2.73%

  • Thursday traded at9.87, up +0.51% after Wednesday traded at 9.82, down -2.58% after Tuesday traded at 10.08, up +5.88% after Monday traded at 9.52, up +3.25% and last Friday traded at 9.22, flat at 0.00% …

 

Welcome to another day of the sector’s roller coaster …

… The iShares Russell 2000 (IWM) indicated:

·         Friday was up +0.40%

·         Thursday was up +1.69%

·         Wednesday was up +0.01%

·         Tuesday was down -0.14%

·         Monday was up +0.17%

·         Last Friday was up +0.21%

 

… The iShares NASDAQ Biotechnology (IBB) indicated:

·         Friday was up +0.67%

·         Thursday was up +0.29%

·         Wednesday was up +0.45%

·         Tuesday was up +1.88%

·         Monday was down -1.33%

·         Last Friday was down -0.13%

 

 

The count - decliners versus gainers:

……. look at the differences in decliners:

·         Friday’s decliners ranged from -0.51% <ATHX -$0.01> to -7.28% <CYTX -$0.028> in 21 equities;

·         Thursday’s decliners ranged from -0.17% <BLUE -$0.30> to -6.47% <ADVM -$0.009> in 15 equities;

·         Wednesday’s decliners ranged from -0.17% <BLFS -$0.01> to -13.23% <KOOL -$0.50 > in 18 equities;

·         Tuesday’s decliners ranged from -0.28% <JUNO -$0.14> to -5.84% < BLCM -$0.55> in 18 equities;

·         Monday’s decliners ranged from -0.11%% <BLCM -$0.01> to -27.19% <CYTX -$0.13> in 26 equities;

·         Last Friday’s decliners ranged from -0.28% <BCLI -$0.01> to -20.88% <RGNX -$7.35> in 20 equities;

Versus

… Look at the percentage’s (%) and spreads …

·         Friday’s gainers ranged from +0.67% <BLCM +$0.06> to +11.27% <XON +$1.49> in 19 equities;

·         Thursday’s gainers ranged from +0.34% <BLCM +$0.03> to +12.67% <ISCO +$0.19> in 22 equities;

·         Wednesday’s gainers ranged from +0.11% <BLCM +$0.01> to +10.12% <NWBO +$0.031> in 20 equities;

·         Tuesday’s gainers ranged from +0.68% <VSTM +$0.02> to +12.84% <KOOL +$0.43> in 22 equities;

·         Monday’s gainers ranged from +0.08% <ONCE +$0.04> to +9.16% <BTX +$0.23> in 13 equities;

·         Last Friday’s gainers ranged from +0.61% <JUNO +$0.29> to +73.75% <CYTX +$0.20> in 18 equities;

                                  

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.